Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld

Treatment & access

• Treatments offeredEsketamine nasal spray (Spravato®)
• Access routeTrial
• Cost & coverage (registry status)Free within clinical trial
• Websitehttps://evkb.de

Related listings

These records belong to the same organisation. They are listed separately because each is a distinct programme or location.

• Another programme at this clinicEvangelisches Klinikum Bethel (EvKB), Universitätsklinik für Psychiatrie und Psychotherapie — Esketaminsprechstunde (PNA) : Spravato®

About this provider

Compiled from the registry data on this page.

This entry describes a clinical trial site: Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld, Bielefeld, Germany. The site takes part in CTIS trial 2023-506617-21-00, a randomised controlled trial of a six-week intensified pharmacological treatment for major depressive disorder, compared to treatment as usual, after a first-time failure of first-line treatment (sponsor: Universitair Medisch Centrum Utrecht). The treatment studied is esketamine (Spravato); access runs through enrolment in the trial, and participation is free of charge within it. The CTIS public record in the EU Clinical Trials Information System is the registry source cited. Last verification of this entry: 2026-07-29.

What to prepare before you enquire

• A referral or the contact details of your treating clinician
• A list of medications you have tried (names, doses, duration)
• A short diagnosis summary or discharge letters

The research team confirms eligibility against your medical records at a screening visit.

Send documents directly to the provider when they reply. We never ask you to upload medical records.